Mersana Therapeutics (FRA:0M4) EV-to-EBIT : -1.08 (As of Apr. 27, 2024)

View and export this data going back to 2017. Start your Free Trial

What is Mersana Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Mersana Therapeutics's Enterprise Value is €168.89 Mil. Mersana Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-155.76 Mil. Therefore, Mersana Therapeutics's EV-to-EBIT for today is -1.08.

The historical rank and industry rank for Mersana Therapeutics's EV-to-EBIT or its related term are showing as below:

FRA:0M4' s EV-to-EBIT Range Over the Past 10 Years
Min: -21.03 Med: -2.22 Max: 2.67
Current: -1.08

During the past 9 years, the highest EV-to-EBIT of Mersana Therapeutics was 2.67. The lowest was -21.03. And the median was -2.22.

FRA:0M4's EV-to-EBIT is ranked worse than
100% of 443 companies
in the Biotechnology industry
Industry Median: 8.19 vs FRA:0M4: -1.08

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Mersana Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was €84.40 Mil. Mersana Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-155.76 Mil. Mersana Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -184.55%.

Mersana Therapeutics EV-to-EBIT Historical Data

The historical data trend for Mersana Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mersana Therapeutics EV-to-EBIT Chart

Mersana Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-6.01

-18.17

-1.89

-1.85

-0.62

Mersana Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															-1.85	-1.00	-0.68	0.28	-0.62

Competitive Comparison of Mersana Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, Mersana Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mersana Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mersana Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Mersana Therapeutics's EV-to-EBIT falls into.

Mersana Therapeutics EV-to-EBIT Calculation

Mersana Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	168.890	/	-155.757
	=	-1.08

Mersana Therapeutics's current Enterprise Value is €168.89 Mil.
Mersana Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-155.76 Mil.

Mersana Therapeutics (FRA:0M4) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Mersana Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-155.757	/	84.397784
	=	-184.55 %

Mersana Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was €84.40 Mil.
Mersana Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-155.76 Mil.

Mersana Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Mersana Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Mersana Therapeutics (FRA:0M4) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mersana Therapeutics Inc (FRA:0M4) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

MRSN:USA

Address

840 Memorial Drive, Cambridge, MA, USA, 02139

Website

https://www.mersana.com

Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.

Mersana Therapeutics (FRA:0M4) Headlines

No Headlines